<DOC>
	<DOCNO>NCT02019602</DOCNO>
	<brief_summary>The primary purpose ass whether transfer Certolizumab Pegol ( CZP ) pregnant woman receive treatment Cimzia® across placenta infant evaluate concentration CZP plasma infant birth .</brief_summary>
	<brief_title>A Multicener , Postmarketing Study Evaluating Transfer Cimzia From Mother Infant Via Placenta</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>An IRB/IEC approve write Informed Consent form maternal subject infant ( ) sign date subject . Where applicable , write Informed Consent form respect infant ( ) also sign date holder parental right designate maternal subject Subject consider reliable capable adhere protocol visit schedule accord judgment Investigator Subject female ≥18 year time inform consent Subject ≥30 week pregnant singleton twin time inform consent Subject treat Certolizumab Pegol ( CZP ) per current approve prescribing Information Subject start decide continue treatment CZP independently prior participate study accordance treat physician Subject expect receive CZP least 35 day prior expect delivery ( date injection count Day 1 ) Additional criterion confirm prior first sample infant Visit 2 ( delivery/birth ) : Subject delivers live bear infant ( ) near term ( ≥34 week gestation ) Subject receive CZP within 35 day delivery ( date injection count Day 1 ) Subject receive contraindicated medication Subject participate study investigational medicinal product ( IMP ) medical device within previous 30 day 5 halflives ( whichever longer ) prior Screening currently participate another study IMP medical device unless study UCB UP0016 [ NCT02154425 ] registry study Subject obstetrical psychiatric condition , infant ( ) medical condition , opinion Investigator , could jeopardize would compromise subject 's ability participate study outcome pregnancy Subject history chronic alcohol abuse drug abuse pregnancy Subject pregnancyrelated clinically significant abnormality note obstetric ultrasound , image assessment , subject significant laboratory abnormality pregnancy , judge Investigator Subject take take medication strong positive evidence human fetal risk teratogenicity ( e.g. , methotrexate leflunomide ) pregnancy Subject evidence condition suggest chronic acute uteroplacental insufficiency intrauterine growth restriction , severe maternal hypertensive disorder pregnancy , abruption Subject document history primary secondary antiphospholipid syndrome hypercoagulable state Subject receive treatment biological therapeutic agent , include antiTNFs certolizumab pegol ( CZP ) , pregnancy Subject previously participate study Subject positive indeterminate QuantiFERON®TB GOLD In Tube test Screening . In case indeterminate result , retest allow time permit ; 2 result indeterminate require exclusion subject Subject know tuberculosis ( TB ) infection , high risk acquire TB infection , latent TB infection ( LTB ) . If test within 6 month prior Screening test negative TB , change subject 's clinical status , social , family , travel history , need additional TB test Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cimzia®</keyword>
	<keyword>CZP</keyword>
	<keyword>Placental transfer</keyword>
	<keyword>Autoimmune diseases pregnancy</keyword>
</DOC>